EDITAS MEDICINE, INC. (EDIT) News Headlines

▮ More

Date

Headline

1/9/2023 8:49:36 AM Editas Medicine To Reduce Headcount By 20% As Part Of Reprioritization, CSO To Stepdown

1/9/2023 8:22:08 AM Editas Medicine To Reduce Headcount By About 20%

11/17/2022 7:24:52 AM Editas Medicine Announces Clinical Data Demonstrating Proof Of Concept Of EDIT-101 From Phase 1/2 BRILLIANCE Trial

4/11/2022 11:11:49 AM Editas Medicine Stock Slips Nearly 6%

3/1/2022 7:33:33 AM Pre-market Movers: GDRX, TACO, AMBA, MULN, SMLR…

2/8/2022 7:39:50 AM Pre-market Movers: SLQT, VDLR, AREB, UCL, SOPA…

12/20/2021 7:06:56 AM Editas Medicine: FDA Clears IND Application For EDIT-301 For Transfusion-Dependent Beta Thalassemia

12/13/2021 7:24:15 AM Pre-market Movers: ARNA, FHTX, PTPI, BDR, BLUE…

9/29/2021 10:57:57 AM Editas Medicine Slips 13% Despite Positive Data On EDIT-101 Trial

9/29/2021 6:11:25 AM Pre-market Movers: GOVX, ITRM, GREE, RGS, MTNB…

6/28/2021 10:05:13 AM Editas Medicine Gains 10%

2/8/2021 8:07:12 AM Editas Medicine Appoints James Mullen As CEO

1/20/2021 10:56:26 PM Editas Medicine Prices Public Offering Of 3.5 Mln Shares At $66/Shr

1/12/2021 1:32:37 AM BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch

1/11/2021 6:11:09 AM Editas Medicine Says Chief Scientific Officer Charles Albright Is Stepping Down On January 15

1/11/2021 6:09:16 AM Editas Says FDA Cleared Initiation Of Safety Phase Of EDIT-301 Clinical Trial

Older Articles

Editas Medicine, Inc. (EDIT)